Loading…
for educational and safety purposes
2C-E and 2C-I both come up in the same conversations; they overlap on Serotonin. 2C-E: 2C-E is one of the more potent and intense members of the 2C family, bearing an ethyl group at the 4-position of the 2,5-dimethoxyphenethylamine scaffold. 2C-I: 2C-I is a widely encountered 2C-series psychedelic phenethylamine bearing an iodine substituent at the 4-position.
2C-E is one of the more potent and intense members of the 2C family, bearing an ethyl group at the 4-position of the 2,5-dimethoxyphenethylamine scaffold. It acts mainly as a 5-HT2A receptor agonist, with the 2C series showing nanomolar affinity and partial-agonist activity at 5-HT2A and 5-HT2C receptors, and it is noted for deep and sometimes challenging effects, a substantial body load, and a comparatively narrow margin between a moderate and an overwhelming experience. It shows measurable monoamine oxidase inhibition in vitro, which may contribute to interaction risks. It has been implicated in cases of severe intoxication, and clinical toxicology reviews associate high doses of 2C compounds with agitation, seizures, hyperthermia, and an excited-delirium presentation in the most serious cases. The compound and its rigidified 2C-E-FLY analog have been characterized analytically for metabolism and urinary detection.
2C-I is a widely encountered 2C-series psychedelic phenethylamine bearing an iodine substituent at the 4-position. It acts principally as a 5-HT2A receptor agonist and reliably induces the 5-HT2A-mediated head-twitch response in mice, a behavioral proxy for hallucinogenic activity that is fully blocked by the selective antagonist M100907. Its scaffold is of particular pharmacological interest because N-benzylation to form 25I-NBOMe increases 5-HT2A affinity and in vivo potency by more than an order of magnitude, yielding a far more dangerous derivative that is sometimes mis-sold as 2C-I. 2C-I itself is characterized by bright, colorful visuals with a moderate stimulating quality, is metabolized largely via CYP2D6, and produces only limited monoamine oxidase inhibition. It is detectable in the urine of users among panels of 2C designer drugs.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
agonist
agonist
agonist
agonist
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.